• About the Firm
• Global Locations
• Perspectives
• Media
• Careers
• Alumni
• Contact Us

• Industries
  • Automotive
  • Aviation, Aerospace & Defense
  • Communications, Media & Technology
  • Energy
  • Financial Services
  • Health and Life Sciences
  • Industrial Products
  • Retail & Consumer Products
  • Surface Transportation
• Capabilities
  • Actuarial
  • Business Transformation
  • Corporate Finance & Restructuring
  • Delta
  • Finance & Risk
  • Leadership Development
  • Marketing & Sales
  • Operations & Technology
  • Strategy

Login | Worldwide

Life Sciences > Leading medical device and equipment manufacturer: Enhanced profitability

• Automotive
• Aviation, Aerospace & Defense
• Communications, Media & Technology
• Energy
• Financial Services
• Health and Life Sciences
• Industrial Products
• Retail & Consumer Products
• Surface Transportation

 

Leading medical device and equipment manufacturer: Enhanced profitability

Oliver Wyman counseled a leading medical device and equipment manufacturer to enhance profitability through improved sourcing and organizational restructuring. Our expertise in benchmarking, portfolio value growth, and acquisition strategies helped to significantly improve our client’s competitive position.

Related Practice Areas

Life Sciences Insights

Options for the Design and Financing of an H5N1 Vaccine Stockpile: Key Findings and Study Methodology

Download >

Global Post-Eradication IPV Supply and Demand Assessment: Integrated Findings

Download >

Influenza Vaccine Supply and Demand: Summary of Findings

Download >

Licensing to Win

Download >

Influenza Vaccine Strategies for Broad Global Access

Download >

Beyond the Blockbuster

Which pharmaceutical business models will emerge over the decade, and the implications for winning strategies

Download >

Rewriting the Rules

A widely covered study into the economics of in-house R&D versus in-licensing, and the implications for the industry structure and pharmaceutical business models

Download >

Structural Shift: Promising Yet Challenging New Markets for Vaccines

Rethink approaches to the vaccine sector for sustained, profitable growth

Download >

From Promise to Persistence: Sight Line to Higher Profit in Pharmaceuticals

Increase revenues 15% to 25% higher than expectations with high impact strategies.

Request a copy >

Careers

Make an impact on your career. Find out more about what we offer.

Home | Terms of Use | Site map |
Copyright © 2010 Oliver Wyman Group